Cancer Advisor

Last Updated: May 2026 Cancer treatment is rapidly evolving from a “one-drug, one-target” model into a multi-modal systems approach. While immunotherapy has transformed outcomes for some patients, many tumors remain resistant or eventually develop immune escape mechanisms. Combining repurposed drugs with precision oncology—targeted therapies or immunotherapies—holds transformative potential by exploiting synergistic effects to improve efficacy, overcome resistance, and expand treatment options for rare and complex cancers. Researchers are now exploring whether drugs such as metformin, ivermectin, mebendazole, statins, and aspirin could help enhance immune responses, alter the tumor microenvironment, and improve the effectiveness of checkpoint inhibitors and other cancer therapies. Although much of the evidence remains preliminary, this emerging field reflects a broader shift toward precision oncology and combination therapy. What Is Immunotherapy? Immunotherapy refers to treatments tha...

Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: July 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the preclin...

Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...